Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Alho H, Sinclair D, Vuori E, Holopainen A.

Drug Alcohol Depend. 2007 Apr 17;88(1):75-8. Epub 2006 Oct 19.

PMID:
17055191
2.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
3.

A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

Simojoki K, Vorma H, Alho H.

Subst Abuse Treat Prev Policy. 2008 Jun 17;3:16. doi: 10.1186/1747-597X-3-16.

4.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
5.

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia.

Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):44-9. doi: 10.1016/j.drugalcdep.2010.03.014. Epub 2010 May 15.

PMID:
20478668
6.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
7.

Buprenorphine and naloxone interactions in opiate-dependent volunteers.

Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ.

Clin Pharmacol Ther. 1996 Jul;60(1):105-14.

PMID:
8689806
8.

A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone).

Welsh C, Sherman SG, Tobin KE.

Addiction. 2008 Jul;103(7):1226-8. doi: 10.1111/j.1360-0443.2008.02244.x.

PMID:
18554353
9.

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.

Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27.

PMID:
21112758
10.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND.

J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.

11.
12.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
13.
14.

The diversion and injection of a buprenorphine-naloxone soluble film formulation.

Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, White N, Degenhardt L.

Drug Alcohol Depend. 2014 Mar 1;136:21-7. doi: 10.1016/j.drugalcdep.2013.12.005. Epub 2014 Jan 8.

PMID:
24461476
15.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
16.

Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.

Med J Aust. 2009 Aug 3;191(3):161-5.

PMID:
19645647
17.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
18.

A trial of integrated buprenorphine/naloxone and HIV clinical care.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S184-90.

PMID:
17109305
19.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
20.

Buprenorphine and naloxone interactions in methadone maintenance patients.

Mendelson J, Jones RT, Welm S, Brown J, Batki SL.

Biol Psychiatry. 1997 Jun 1;41(11):1095-101.

PMID:
9146820

Supplemental Content

Support Center